- $1.21bn
- $1.19bn
- $174.54m
Annual cashflow statement for Enfusion, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 12.7 | 4.06 | -282 | -13.3 | 9.25 |
| Depreciation | |||||
| Non-Cash Items | 0.291 | 1.07 | 293 | 26.7 | 15.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.8 | -5.76 | -14.7 | -5.6 | -9.44 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | 12.3 | 1.67 | -0.318 | 14.2 | 25.6 |
| Capital Expenditures | -4.43 | -5.07 | -8.01 | -7.93 | -9.67 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Cash from Investing Activities | -4.43 | -5.07 | -8.01 | -7.93 | -9.67 |
| Financing Cash Flow Items | -11.1 | -4.92 | -13.8 | -7.96 | -60.4 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -7.54 | 11.6 | 58.8 | -7.96 | -43.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.25 | 8.04 | 50.4 | -1.82 | -26.9 |